Prognostic factors with a well documented significance for survival in patients with small cell lung cancer (SCLC) include performance status (PS), extent of disease, serum lactate dehydrogenase (LDH), serum alkaline phosphatase (AP), plasma sodium (Na) and age (Souhami et al., 1985 , 0sterlind & Andersen, 1986 , Cerny et al., 1987 , Vincent et al., 1987 . These variables have all been assessed in multivariate analysis.
With respect to tumour markers serum neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and alpha-lacid glycoprotein (AGP) have separately been found important for the prognosis. A negative correlation was described between initial high or low levels of NSE and survival (Akoun et al., 1985) . Contradictory results have been found for CEA (Sculier et al., 1985 , Bucceri et al., 1987 , while a normalization of serum AGP level during chemotherapy involved a longer disease-free survival (Ganz et al., 1984) . These investigations on tumour markers are based on univariate analysis which limits the conclusions to be drawn.
Accordingly, the present study was performed using a multivariate analysis. The aim was to assess the prognostic significance on survival of the above mentioned tumour markers and compare their influence with that of already well established prognostic factors. 
Treatment
Patients received combination chemotherapy including cisplatinum, etoposide, vincristine, and lomustine (Osterlind et al., 1986; Pedersen et al., 1987) .
Tumour marker assessment Serum NSE was measured by a radioimmunoassay (NSE-RIA, Pharmacia Diagnostics AB, Uppsala, Sweden), serum CEA by the Amerwell CEA-RIA (Amersham International Amersham, Bucks, UK) and serum alpha-l-acid glycoprotein by radial immunodiffusion using antisera obtained from Daco, Copenhagen, Denmark. The following values were regarded as normal limits of the bio-markers: NSE<12.5ngml-1, CEA<5.Ongml-1 and AGP<1.4gl-1. In addition to these 3 tumour markers the following variables were included in the prognostic factor analysis: serum LDH and AP, plasma sodium, age, sex, PS and disease stage. The cut-off values used for routinely measured biochemical samples were our laboratory's normal limits of these variables.
Statistical methods
The prognostic influence of each variable was first investigated in univariate analysis. A significance level of P<0.05 was applied. Survival in different categories based on the individual variable were studied by use of life tables and compared by log rank analysis (Peto et al., 1977) . The test for trend (Tarone, 1975) was used in variables enabling a ranking of patients into more than two groups. Continuous variables such as LDH, NSE, AP, AGP and CEA were categorized as 'O' if normal while raised values were categorized by the factor of increase, maximally '3'. In NSE the cutoff levels were: 12.5ngml-1, 50.Ongml-1 and 90.Ongml-1.
Cox's proportional hazards model was applied for the multiple regression analysis (Cox, 1972) . A backward stepwise elimination procedure was used and estimation of regression coefficients was based on the maximum likelihood method. Exclusions of variables from the model were based on the partial likelihood ratios test (Andersen & Waeth, 1984) . The BMDP statistical software package was used for the analyses (Berkeley, 1981) .
Results
The pretreatment characteristics are listed in Table I . The median duration of follow-up of all patients was 308 days (Lanzotti et al., 1977 , Stanley, 1980 , Souhami et al., 1985 , 0sterlind & Andersen, 1986 , Cerny et al., 1987 , Vincent et al., 1987 . The Veterans Administration lung study group evaluated 77 possible prognostic factors in 5,000 patients. After regression analysis three were significant: PS, stage of disease and prior weight loss. The two early investigations from 1977 and 1980, unfortunately, include both patients with non-SCLC and with SCLC. There may, furthermore, be some histological discrepancies, as both studies are dated before 1981 when the current guidelines for histological classification of bronchogenic tumours was published (WHO, 1981) . The four series published in 1985-87 were restricted to patients with SCLC and all proved the importance of PS.
Our observation of strong relationship between both the serum levels of NSE and LDH (correlation coefficient=0.72) and their influence on survival (-0.38) indicates that the two variables may contain similar information and supports the role of NSE as an apparently important prognostic factor. Once NSE was included in he model, LDH did not provide additional significant information.
Significant prognostic influence of LDH has been confirmed by two recent series. Thus Osterlind & Andersen (1986) found major influence of LDH among 18 variables in 778 cases, and LDH was also among the six most important variables among 60 investigated features in a study on 407 patients (Cerny et al., 1987) .
Our CEA measurements were not related to survival. The conflicting results of the prognostic influence of CEA (Sculier et al., 1985 , Buccheri et al., 1987 may be derived from differences in methods and variables included in the investigation, and we suspect that CEA has only inferior influence on the prognosis in SCLC.
We could not confirm the importance of AP described by Souhami et al. (1985) and by Vincent et al. (1987) . None of the two studies did, however, include LDH in the analysis. Na, AGP, age and sex did not add critical information in this series of only 86 patients.
Patients with LD and ED did not have proportional death hazards and the Cox model therefore had to be stratified according to disease extent. The number of cases analysed in this series was regarded insufficient to establish a new prognostic index.
In conclusion, high levels of NSE and poor performance are of great importance for predicting the prognosis in SCLC. Compared to LDH, NSE values were increased in a greater fraction of our patients and therefore seems to be a more informative prognostic factor than LDH. It may therefore be reasonable to suggest that NSE should be included in future studies of prognostic factors and in clinical trials on SCLC.
